Cardiac Failure Review最新文献

{"title":"Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach.","authors":"Estefania Oliveros, Yevgeniy Brailovsky, Paul Scully, Evgenia Nikolou, Ronak Rajani, Julia Grapsa","doi":"10.15420/cfr.2020.09","DOIUrl":"10.15420/cfr.2020.09","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) is a debilitating viral infection and, to date, 628,903 people have died from it, numbers that cannot yet be compared to the 50 million who died in the 1918 flu pandemic. As COVID-19 became better understood, cardiovascular manifestations associated with it were identified. This led to a complete healthcare restructuring with virtual clinics and changes to the triaging of critically ill patients. There are a lot of questions over how COVID-19 affects patients with heart failure (HF) as this condition is a leading cause of cardiovascular death. This review describes the cardiovascular implications of COVID-19 and new practices surrounding the use of telehealth to follow up and triage patients with HF. Current practices supported by medical societies, the role of angiotensin-converting enzyme inhibitors and, finally, a brief note regarding the management of advanced HF patients will also be discussed.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e22"},"PeriodicalIF":4.2,"publicationDate":"2020-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/7d/cfr-06-e22.PMC7479531.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?","authors":"Sebastiaan Hc Klaassen,&nbsp;Dirk J van Veldhuisen,&nbsp;Hans LA Nienhuis,&nbsp;Maarten P van den Berg,&nbsp;Bouke Pc Hazenberg,&nbsp;Peter van der Meer","doi":"10.15420/cfr.2019.16","DOIUrl":"https://doi.org/10.15420/cfr.2019.16","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of cardiac ATTR amyloidosis is strong if pronounced left ventricular hypertrophy is present in the absence of hypertension. Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. First treatment options for ATTR amyloidosis recently emerged, and showed a reduction in morbidity and mortality, especially if treatment was started in the early stages of disease. In light of these results, screening for ATTR amyloidosis in the general HFpEF population with left ventricular hypertrophy might be useful.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e21"},"PeriodicalIF":0.0,"publicationDate":"2020-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/ee/cfr-06-e21.PMC7479537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits?","authors":"Oren Caspi,&nbsp;Doron Aronson","doi":"10.15420/cfr.2019.22","DOIUrl":"https://doi.org/10.15420/cfr.2019.22","url":null,"abstract":"<p><p>The use of opioids in acute pulmonary oedema is considered standard therapy by many physicians. The immediate relieving effect of morphine on the key symptomatic discomfort associated with acute heart failure, dyspnoea, facilitated the categorisation of morphine as a beneficial treatment in this setting. During the last decade, several retrospective studies raised concerns regarding the safety and efficacy of morphine in the setting of acute heart failure. In this article, the physiological effects of morphine on the cardiovascular and respiratory systems are summarised, as well as the potential clinical benefits and risks associated with morphine therapy. Finally, the reported clinical outcomes and adverse event profiles from recent observational studies are discussed, as well as future perspectives and potential alternatives to morphine in the setting of acute heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2020-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/ac/cfr-06-e20.PMC7407569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38246444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.","authors":"Zoltán Papp,&nbsp;Piergiuseppe Agostoni,&nbsp;Julian Alvarez,&nbsp;Dominique Bettex,&nbsp;Stefan Bouchez,&nbsp;Dulce Brito,&nbsp;Vladimir Černý,&nbsp;Josep Comin-Colet,&nbsp;Marisa G Crespo-Leiro,&nbsp;Juan F Delgado,&nbsp;Istvan Édes,&nbsp;Alexander A Eremenko,&nbsp;Dimitrios Farmakis,&nbsp;Francesco Fedele,&nbsp;Cândida Fonseca,&nbsp;Sonja Fruhwald,&nbsp;Massimo Girardis,&nbsp;Fabio Guarracino,&nbsp;Veli-Pekka Harjola,&nbsp;Matthias Heringlake,&nbsp;Antoine Herpain,&nbsp;Leo Ma Heunks,&nbsp;Tryggve Husebye,&nbsp;Višnja Ivancan,&nbsp;Kristjan Karason,&nbsp;Sundeep Kaul,&nbsp;Matti Kivikko,&nbsp;Janek Kubica,&nbsp;Josep Masip,&nbsp;Simon Matskeplishvili,&nbsp;Alexandre Mebazaa,&nbsp;Markku S Nieminen,&nbsp;Fabrizio Oliva,&nbsp;Julius-Gyula Papp,&nbsp;John Parissis,&nbsp;Alexander Parkhomenko,&nbsp;Pentti Põder,&nbsp;Gerhard Pölzl,&nbsp;Alexander Reinecke,&nbsp;Sven-Erik Ricksten,&nbsp;Hynek Riha,&nbsp;Alain Rudiger,&nbsp;Toni Sarapohja,&nbsp;Robert Hg Schwinger,&nbsp;Wolfgang Toller,&nbsp;Luigi Tritapepe,&nbsp;Carsten Tschöpe,&nbsp;Gerhard Wikström,&nbsp;Dirk von Lewinski,&nbsp;Bojan Vrtovec,&nbsp;Piero Pollesello","doi":"10.15420/cfr.2020.03","DOIUrl":"https://doi.org/10.15420/cfr.2020.03","url":null,"abstract":"<p><p>Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2020-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/be/cfr-06-e19.PMC7374352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38203091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart.","authors":"Emilia D'Elia,&nbsp;Michele Senni","doi":"10.15420/cfr.2020.11","DOIUrl":"https://doi.org/10.15420/cfr.2020.11","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has become a pandemic affecting every country in the world. In the province of Bergamo, Italy, more than 2,200 cases of COVID-19 have been reported, which include more than 300 deaths. Most hospitalisations have been at the Papa Giovanni XXIII Hospital. This has imposed a significant burden on our hospital in terms of healthcare personnel, dedicated spaces (including intensive care areas) and time spent by clinicians, who are committed to assisting COVID-19 patients. In this short expert opinion, the authors will focus on new insights related to COVID-19 and the cardiovascular system, and try to investigate the grey areas and uncertainties in this field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e18"},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/24/cfr-06-e18.PMC7341260.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019-associated Acute Respiratory Distress Syndrome: An Initial US Experience at a High-volume Centre.","authors":"Yang Yang,&nbsp;Aniket S Rali,&nbsp;Christian Inchaustegui,&nbsp;Javid Alakbarli,&nbsp;Subhasis Chatterjee,&nbsp;James P Herlihy,&nbsp;Joggy George,&nbsp;Alexis Shafii,&nbsp;Ajith Nair,&nbsp;Leo Simpson","doi":"10.15420/cfr.2020.16","DOIUrl":"https://doi.org/10.15420/cfr.2020.16","url":null,"abstract":"In select COVID-19 patients suffering from severe ARDS refractory to conventional therapy, ECMO might be an outcome altering therapy. Respiratory ECMO Survival Prediction (RESP) score appears to be a reliable prognostication tool in selecting COVID-19 patients most likely to benefit from ECMO. Early and frequent evaluation of critically ill COVID-19 patients for ECMO therapy could facilitate timely initiation, and ultimately, favourable outcomes. ECMO is a finite resource, and thus must be used judiciously, especially in the midst of a pandemic where all resources are stretched thin.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e17"},"PeriodicalIF":0.0,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/84/cfr-06-e17.PMC7341259.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine, Artificial Intelligence and Humanisation of Clinical Pathways in Heart Failure Management: Back to the Future and Beyond.","authors":"Domenico D'Amario,&nbsp;Francesco Canonico,&nbsp;Daniele Rodolico,&nbsp;Josip A Borovac,&nbsp;Rocco Vergallo,&nbsp;Rocco Antonio Montone,&nbsp;Mattia Galli,&nbsp;Stefano Migliaro,&nbsp;Attilio Restivo,&nbsp;Massimo Massetti,&nbsp;Filippo Crea","doi":"10.15420/cfr.2019.17","DOIUrl":"https://doi.org/10.15420/cfr.2019.17","url":null,"abstract":"<p><p>New technologies have been recently introduced to improve the monitoring of patients with chronic syndromes such as heart failure. Devices can now be employed to gather large amounts of data and data processing through artificial intelligence techniques may improve heart failure management and reduce costs. The analysis of large datasets using an artificial intelligence technique is leading to a paradigm shift in the era of precision medicine. However, the assessment of clinical safety and the evaluation of the potential benefits is still a matter of debate. In this article, the authors aim to focus on the development of these new tools and to draw the attention to their transition in daily clinical practice.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e16"},"PeriodicalIF":0.0,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/d1/cfr-06-e16.PMC7312813.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38114551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Would You Prescribe Mobile Health Apps for Heart Failure Self-care? An Integrated Review of Commercially Available Mobile Technology for Heart Failure Patients.","authors":"Andrea Mortara,&nbsp;Lucia Vaira,&nbsp;Vittorio Palmieri,&nbsp;Massimo Iacoviello,&nbsp;Ilaria Battistoni,&nbsp;Attilio Iacovoni,&nbsp;Francesca Macera,&nbsp;Daniele Pasqualucci,&nbsp;Mario Bochicchio,&nbsp;Renata De Maria","doi":"10.15420/cfr.2019.11","DOIUrl":"https://doi.org/10.15420/cfr.2019.11","url":null,"abstract":"<p><p>Treatment of chronic diseases, such as heart failure, requires complex protocols based on early diagnosis; self-monitoring of symptoms, vital signs and physical activity; regular medication intake; and education of patients and caregivers about relevant aspects of the disease. Smartphones and mobile health applications could be very helpful in improving the efficacy of such protocols, but several barriers make it difficult to fully exploit their technological potential and produce clear clinical evidence of their effectiveness. App suppliers do not help users distinguish between useless/dangerous apps and valid solutions. The latter are few and often characterised by rapid obsolescence, lack of interactivity and lack of authoritative information. Systematic reviews can help physicians and researchers find and assess the 'best candidate solutions' in a repeatable manner and pave the way for well-grounded and fruitful discussion on their clinical effectiveness. To this purpose, the authors assess 10 apps for heart failure self-care using the Intercontinental Marketing Statistics score and other criteria, discuss the clinical effectiveness of existing solutions and identify barriers to their use in practice and drivers for change.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/75/cfr-06-e13.PMC7277786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apps and Online Platforms for Patients with Heart Failure.","authors":"Nida Ahmed,&nbsp;Sabahat Ahmed,&nbsp;Julia Grapsa","doi":"10.15420/cfr.2019.15","DOIUrl":"https://doi.org/10.15420/cfr.2019.15","url":null,"abstract":"<p><p>The use of the internet for health advice and information has burgeoned over recent years. This corresponds with an increasing number of people living with heart failure and, in the context of a greater focus on patient engagement, producing accurate online health information is becoming vitally important. To help meet this need, major cardiology societies have designed dedicated, patient-specific areas on their websites. This article aims to provide an overview of the patient information resources from three main professional societies: the European Society of Cardiology, American Heart Association and American College of Cardiology. A summary of the content of these dedicated websites and two smartphone apps is provided, along with a brief look into the future role of these technologies and resources in supporting both patients and their clinicians in the management of heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e14"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/6a/cfr-06-e14.PMC7277783.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Myocardial Injury in Coronavirus Disease 2019.","authors":"Aniket S Rali,&nbsp;Sagar Ranka,&nbsp;Zubair Shah,&nbsp;Andrew J Sauer","doi":"10.15420/cfr.2020.10","DOIUrl":"https://doi.org/10.15420/cfr.2020.10","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) predominantly presents with symptoms of fever, fatigue, cough and respiratory failure. However, it appears to have a unique interplay with cardiovascular disease (CVD); patients with pre-existing CVD are at highest risk for mortality from COVID-19, along with the elderly. COVID-19 contributes to cardiovascular complications including arrhythmias, myocardial dysfunction and myocardial inflammation. Although the exact mechanism of myocardial inflammation in patients with COVID-19 is not known, several plausible mechanisms have been proposed based on early observational reports. In this article, the authors summarise the available literature on mechanisms of myocardial injury in COVID-19.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e15"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/f7/cfr-06-e15.PMC7277776.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38047294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}